Sionna Therapeutics (NASDAQ:SION) Earns Buy Rating from Analysts at TD Cowen

TD Cowen assumed coverage on shares of Sionna Therapeutics (NASDAQ:SION - Free Report) in a report published on Tuesday, Marketbeat Ratings reports. The brokerage issued a buy rating on the stock.

A number of other brokerages have also commented on SION. Guggenheim assumed coverage on shares of Sionna Therapeutics in a research note on Tuesday. They set a "buy" rating and a $45.00 price target for the company. Stifel Nicolaus assumed coverage on shares of Sionna Therapeutics in a research report on Tuesday. They set a "buy" rating and a $32.00 target price for the company.

Sionna Therapeutics Stock Performance

Shares of NASDAQ SION traded up $0.62 during midday trading on Tuesday, hitting $16.27. 327,316 shares of the stock traded hands, compared to its average volume of 225,817. Sionna Therapeutics has a one year low of $13.20 and a one year high of $25.19.

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.